Trials / Completed
CompletedNCT03004820
Prevention of Ischemic Conditions in Non-disabling Stroke/Transient Ischemic Attack With Remote Ischemic Conditioning
Feasibility of Applying Remote Ischemic Conditioning in Secondary Prevention in Patients With Minor Ischemic Stroke or Transient Ischemic Attack -A Single-arm Futility Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 167 (actual)
- Sponsor
- Capital Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-labeled and phase II futility study. Application of Remote ischemic conditioning (RIC) as an adjunctive therapy to medication were involved in the study. The study is to test whether RIC is effective in preventing ischemic evens after a minor ischemic stroke/transient ischemic attack within 3 months and to explore the safety and compliance of chronic RIC. Medication strategy is based on physician's best judgement.
Detailed description
This is a single-arm, open-labeled and phase II futility study. Application of Remote ischemic conditioning (RIC) as an adjunctive therapy to medication were involved in the study. RIC consisted of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral upper limbs twice a day. The study is to test whether RIC is effective in preventing ischemic evens after a minor ischemic stroke/transient ischemic attack within 3 months and to explore the safety and compliance of chronic RIC. Medication strategy is based on physician's best judgement.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Remote Ischemic Conditioning | RIC consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral upper limbs twice a day. Medication strategy is based on physician's best judgement. |
Timeline
- Start date
- 2016-12-06
- Primary completion
- 2017-10-19
- Completion
- 2017-10-19
- First posted
- 2016-12-29
- Last updated
- 2018-01-31
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03004820. Inclusion in this directory is not an endorsement.